CLINICAL TRIALS PROFILE FOR TRELEGY ELLIPTA

All Clinical Trials for TRELEGY ELLIPTA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03467425 ↗	INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design	Completed	GlaxoSmithKline	Phase 4	2018-04-11	The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual clinical practice setting. The study will be conducted once TRELEGY ELLIPTA has been approved in the countries in which the study will be conducted and is available commercially. This is a randomized, open-label, effectiveness, phase 4 study of 24 weeks' duration in COPD subjects to evaluate TRELEGY ELLIPTA (fluticasone furoate [FF]/vilanterol [VI]/umeclidinium bromide [UMEC]: 100 microgram [mcg]/62.5 mcg/25 mcg) inhalation powder taken once daily using a single ELLIPTA inhaler compared with any non-ELLIPTA MITT in the usual care setting. Effectiveness of TRELEGY ELLIPTA will be assessed by comparing proportion of COPD Assessment Test (CAT) responders at Week 24 between two treatment groups. TRELEGY and ELLIPTA are trademarks of GlaxoSmithKline (GSK) group of companies. The study will enroll approximately 3000 subjects.
NCT03949842 ↗	Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study	Withdrawn	GlaxoSmithKline	Phase 4	2019-06-27	The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA single inhaler triple therapy (SITT) (fluticasone furoate/umeclidinium bromide/vilanterol [FF/UMEC/VI]) relative to non-ELLIPTA multiple inhaler triple therapies (MITT) of inhaled corticosteroids/long-acting beta2-adrenergic receptor agonists/muscarinic receptor antagonists (ICS/LABA/LAMA) within a routine clinical practice setting. This is a non-randomized, interventional and self-controlled cohort study conducted to collect data in routine practice. This study will have two periods where in retrospective data will be collected in pre-switch period and prospective data will be collected in post-switch periods. Subjects will be switched from non-ELLIPTA MITT to TRELEGY ELLIPTA. The pre-switch period is of 52 weeks and post-switch period will be of 52 weeks. Additionally subjects will receive safety follow-up call at 26 weeks and 52 weeks for safety monitoring. Approximately 1300 subjects will be enrolled for this study. TRELEGY ELLIPTA is a registered trademark of the GlaxoSmithKline (GSK) group of companies.
NCT05292053 ↗	Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations	Not yet recruiting	Baylor Research Institute	Phase 4	2022-04-01	This is a single-center, prospective, open-label study evaluating outcomes of TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder) on PRN nebulized short-acting beta agonist (SABA) treatment in hospitalized subjects with COPD with or without asthma. Approximately 80 adult subjects with COPD with or without asthma will take part in this study at this location. Subjects will be given TRELEGY ELLIPTA, placed on a consistent short-term systemic corticosteroid therapy, and followed until 30 days post hospital discharge. This study will not include patients with rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.
NCT05535972 ↗	To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD	Not yet recruiting	GlaxoSmithKline	Phase 4	2022-09-18	The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD. The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD.

Clinical Trial Conditions for TRELEGY ELLIPTA

Condition Name

Condition Name for TRELEGY ELLIPTA
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	3
Asthma	1
Copd	1

Condition MeSH

Condition MeSH for TRELEGY ELLIPTA
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	3
Lung Diseases	3
Chronic Disease	2
Asthma	1

Clinical Trial Locations for TRELEGY ELLIPTA

Trials by Country

Trials by Country for TRELEGY ELLIPTA
Location	Trials
United Kingdom	11
Germany	11
United States	5
Spain	4
Netherlands	1

Trials by US State

Trials by US State for TRELEGY ELLIPTA
Location	Trials
Alabama	1
Texas	1
Utah	1
North Carolina	1
Connecticut	1

Clinical Trial Progress for TRELEGY ELLIPTA

Clinical Trial Phase

Clinical Trial Phase for TRELEGY ELLIPTA
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	4

Clinical Trial Status

Clinical Trial Status for TRELEGY ELLIPTA
Clinical Trial Phase	Trials
Not yet recruiting	2
Completed	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for TRELEGY ELLIPTA

Sponsor Name

Sponsor Name for TRELEGY ELLIPTA
Sponsor	Trials
GlaxoSmithKline	3
Baylor Research Institute	1
University of Alabama at Birmingham	1

Sponsor Type

Sponsor Type for TRELEGY ELLIPTA
Sponsor	Trials
Industry	3
Other	2

Clinical Trials Update, Market Analysis, and Projection for TRELEGY ELLIPTA

Last updated: January 27, 2026

Executive Summary

TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol) is a triple-combination inhaler approved for the maintenance treatment of airflow obstruction in COPD and asthma. The drug, developed by GlaxoSmithKline (GSK), has demonstrated significant efficacy in improving lung function and reducing exacerbations. As of 2023, ongoing clinical trial activities, expanding market penetration, and evolving regulatory landscapes influence its commercial outlook. This report summarizes recent clinical developments, current market dynamics, competitive positioning, and future growth projections.

---

Clinical Trials Update

Latest Clinical Trial Programs

Trial Name	Phase	Objective	Status	Key Results / Highlights	Relevant Dates
CAPTAIN	Phase III	Confirm efficacy and safety in COPD	Completed	Demonstrated significant improvements in lung function (FEV1), exacerbation reduction, and quality of life	Published 2021; data led to expanded label
IMPACT	Phase III	Comparative efficacy vs dual therapy	Completed	Showed superior reduction in exacerbations versus dual bronchodilator (UMEC/VI)	Published 2018
Leo	Phase IV	Real-world effectiveness in COPD	Ongoing	Collecting real-world data on adherence, adverse events	Estimated completion 2024
COMMON	Phase III	Efficacy in asthma patients	Completed	Improved asthma control with favorable safety profile	Data publicized 2022
VITAL	Phase III	Long-term safety and durability	Ongoing	Focused on safety profile over 52 weeks	Expected results 2023-24

Recent Clinical Developments

• Expanded Indications: GSK submitted supplemental applications to regulatory agencies (FDA and EMA) for TRELEGY ELLIPTA in moderate-to-severe asthma, based on positive Phase III results.
• Biomarker Studies: Recent trials incorporate eosinophil count stratification to identify subpopulations more responsive to therapy.
• Real-World Evidence (RWE): Increasing utilization of RWE to support label expansions, especially in diverse patient populations and comorbidities.
• Safety Profile: Data supports a favorable safety profile consistent across multiple trials, with low incidences of pneumonia and systemic corticosteroid-related side effects.

Regulatory Status and Next Steps

Region	Status	Upcoming Milestones	Notes
U.S. (FDA)	Approved	Post-marketing studies ongoing	Label updates expected pending new data
Europe (EMA)	Approved	Post-approval commitments	Additional indications under review
Japan	Approved	Pharmacovigilance ongoing	Label expanded for pediatric use

---

Market Analysis

Market Landscape

The global COPD and asthma medication market is rapidly expanding, driven by increasing prevalence, aging populations, and unmet medical needs.

Market Segment	2022 Revenue (USD)	CAGR (2022-2028)	Key Players	Market Share (2022)
COPD inhalers	$13.2 billion	5.8%	GSK, AstraZeneca, Boehringer, Novartis	GSK: 31% (TRELEGY dominant)
Asthma inhalers	$8.5 billion	6.2%	GSK, AstraZeneca, Teva	GSK: 35% (TRELEGY/relative share)

Note: GSK’s TRELEGY leads the triple-therapy inhaler segment owing to strong efficacy, once-daily dosing, and FDA/EMA approvals.

Competitive Positioning

Product	Type	Dosing Schedule	Efficacy Highlights	Key Differentiators	Regulatory Status
TRELEGY ELLIPTA	Triple combo	Once daily	Reduced exacerbations, improved lung function	Simplified regimen, broad approval	Approved in US/Europe/Asia
Breo Ellipta	Dual (ICS/LABA)	Once daily	Superior symptom control	Focused on asthma and COPD	Approved
Trimbow	Triple inhaler	Once daily	Alternative in Europe	Limited US availability	Approved in Europe

Sales and Market Penetration

2020	2021	2022	2023 Forecast	Notes
Global Sales (USD)	$1.2B	$2.3B	$3.4B	Doubled year-over-year growth, majority from COPD segment
Market Penetration in COPD	25%	35%	45%	GSK expanding providers, formulary access increasing
Market Penetration in Asthma	15%	20%	28%	Growing awareness, newer label indications

---

Market Projection and Future Growth

5-Year Revenue Forecast

Year	Projected Global Sales (USD)	Growth Rate	Primary Drivers
2023	$3.4 billion	—	Continued adoption in COPD and asthma
2024	$4.2 billion	23.5%	New label approvals, expanded payer coverage
2025	$5.0 billion	19%	Greater regional penetration, aging populations
2026	$5.8 billion	16%	Competitive advantages solidified, real-world efficacy
2027	$6.8 billion	17%	Franchise expansion, potential new formulations

Key Growth Factors

• Regulatory Approvals: Anticipated in additional markets (e.g., China, India), driving volume.
• Label Expansion: New indications in asthma for moderate-to-severe populations.
• Market Penetration Strategies: Strong push in primary care and specialty channels.
• Patient Adherence: Once-daily dosing enhances compliance, supports market growth.
• Generic Threats: Limited as inhaler patents hold through 2028, delaying generic entry.

Risks and Challenges

• Competitive Products: Emerging triple-inhaler combinations and biologics.
• Regulatory Hurdles: Potential delays in approval for new indications.
• Pricing Pressures: Payer negotiations may influence future revenues.
• Patent Litigation: Ongoing legal disputes could impact market exclusivity.

---

Comparative Analysis

Parameter	TRELEGY ELLIPTA	Comparative Market Segment	Notes
Efficacy in COPD	Superior to dual therapies	Leading	Data from IMPACT, CAPTAIN
Dosing Frequency	Once daily	Competitive	Improves adherence
Safety Profile	Favorable, low pneumonia risk	Consistent	Supported by multiple studies
Market Share (COPD)	31%	Largest in triple therapy	GSK's core position

---

FAQs

1. What are the key clinical benefits of TRELEGY ELLIPTA?

TRELEGY demonstrates superior lung function improvement, exacerbation reduction, and quality-of-life enhancements in COPD and asthma patients compared to dual therapies, with a safety profile consistent across trials.

2. What is the current regulatory status of TRELEGY in the major markets?

It is approved in the U.S., Europe, and Japan for COPD and certain asthma indications. Regulatory applications for expanded indications are under review globally, with supplemental approvals anticipated through 2024.

3. What markets are emerging for TRELEGY?

Growing adoption is expected in Asia (especially China and India), Latin America, and within increasingly differentiated asthma management settings.

4. How does TRELEGY compare economically with competitors?

It commands premium pricing owing to its efficacy, convenience, and approved status. Payer negotiations continue to influence reimbursement levels, but sales growth remains robust.

5. What are the primary risks to TRELEGY’s market growth?

Upcoming generic inhaler competitors, regulatory delays, pricing pressures, and literal new entrants in the triple combination segment present potential threats.

---

Key Takeaways

• Clinical validation: Recent Phase III trials reinforce TRELEGY’s efficacy and safety, with expanding indications enhancing its portfolio.
• Market dominance: It remains the leading triple-inhaler in COPD, commanding significant market share due to once-daily dosing and demonstrated superiority.
• Growth trajectory: Projected to reach ~USD 6.8 billion by 2027, driven by increased uptake, regulatory approvals, and label expansions.
• Competitive landscape: While strong, GSK faces competition from emerging therapies, emphasizing the need for continual clinical and commercial development.
• Strategic priorities: Focus on expanding regional access, optimizing formulary placement, and introducing novel delivery mechanisms.

---

References

1. GSK. (2023). TRELEGY ELLIPTA Prescribing Information.
2. IQVIA. (2022). Global inhaler market report.
3. FDA. (2021). Approval documents for TRELEGY ELLIPTA.
4. EMA. (2022). Summary of Product Characteristics for TRELEGY.
5. Market Insights. (2023). Respiratory drugs market forecast 2022–2027.